OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
S. Kilickap,A. Sezer,M. Gümüş,I. Bondarenko,M. Özgüroğlu,M. Gogishvili,H.M. Turk,I. Cicin,D. Bentsion,O. Gladkov,P. Clingan,V. Sriuranpong,N. Rizvi,S. Li,S. Lee,T. Makharadze,S. Paydas,M. Nechaeva,F. Seebach,D.M. Weinreich,G.D. Yancopoulos,G. Gullo,I. Lowy,P. Rietschel Journal of Thoracic Oncology（2021）
AI 理解论文
溯源树
样例
